Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.62 |
| ▸ | AQP1 | P29972 | 2/20 | 0.62 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 10/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636281 | 0.88 | NPY5R (0.64) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL8908378 | 0.88 | NPY5R (0.64) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL2804108 | 0.87 | NPY5R (0.62) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL8899497 | 0.87 | NPY5R (0.62) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8906965 | 0.87 | NPY5R (0.62) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2675360 | 0.87 | NPY5R (0.62) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL6674509 | 0.85 | NPY5R (0.60) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL8901692 | 0.84 | NPY5R (0.72) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| SCHEMBL8901686 | 0.84 | NPY5R (0.72) | NPY5RADRA2AAQP1MCHR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL8899807 | 0.83 | NPY5R (0.71) | NPY5RADRA2AAQP1MCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | NPY5R 312/4885ADRA2A 155/4885AQP1 1174/4885 |
| US-20050059716-A1 | Novel bicyclic cyanoheterocycles, process for their preparation and their use as medicaments | CYP11B2, GOT2, CYP11B1 | NPY5R 1591/4885ADRA2A 539/4885AQP1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.